Business ❯ Pharmaceuticals ❯ Manufacturing

Investment

Eli Lilly Job Creation AstraZeneca Novartis Tariffs Sanofi Domestic Production Infrastructure Supply Boost Expansion Research and Development Merck Merck & Co Moderna Canada Supply chain U.S. Manufacturing

AstraZeneca Invests $2 Billion to Expand Maryland Biologics and Build New Clinical Site

The commitment marks the fourth leg of its $50 billion U.S. expansion targeting operational readiness in 2029.

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

Merck Breaks Ground on $3 Billion Virginia Plant in $70 Billion U.S. Expansion

AstraZeneca Breaks Ground on $4.5 Billion Virginia Plant With Expanded Cancer and Obesity Drug Production

Eli Lilly Chooses Houston for $6.5 Billion Plant to Produce APIs for Orforglipron and Other Drugs

Eli Lilly Picks Virginia for $5 Billion Bioconjugate Plant, First of Four New U.S. Sites

AbbVie to Build $195 Million API Facility in North Chicago

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030